What is the main driver behind the decrease in net earnings despite strong sales growth?

The primary reason for the decline in net earnings is the significant increase in In-Process Research and Development (IPR&D) charges. These charges, totaling $900 million in the second quarter of 2003, are associated with the company's strategic acquisitions, most notably Scios Inc. and Link Spine Group, Inc. These IPR&D expenses are non-deductible for tax purposes, further impacting the effective tax rate and net income.

How have the recent acquisitions impacted the company's financial position?

Recent acquisitions, such as Scios Inc. and Link Spine Group, Inc., have significantly contributed to the growth in total assets and, more specifically, intangible assets, which now represent a larger portion of the company's asset base. While these acquisitions fuel future growth, they also incurred substantial IPR&D charges and increased goodwill on the balance sheet. The company financed these acquisitions through a combination of cash flow from operations, borrowings (including commercial paper and long-term debt), and the assumption of liabilities.

Are there any specific product lines or segments that are performing particularly well or poorly?

The Pharmaceutical segment's operating profit declined due to IPR&D charges and increased sales force expenses, although key drugs like RISPERDAL, TOPAMAX, and LEVAQUIN continue to show strong sales growth. PROCRIT and EPREX sales have declined due to competition and safety concerns, respectively. The Medical Devices & Diagnostics (MD&D) segment is performing very well, with strong growth in joint reconstruction, spine, and sports medicine products, boosted by the FDA approval of the CYPHER drug-eluting coronary stent. The Consumer segment also showed growth, particularly in skincare with the AVEENO brand and wound care products.

What is the company's outlook regarding shareholder returns?

Johnson & Johnson continues to prioritize shareholder returns. In the second quarter of 2003, the company declared a regular cash dividend of $0.24 per share, representing a 17.1% increase over the prior year. This marks the 41st consecutive year of cash dividend increases, and the company expects to continue this practice.

JNJ 10-Q Quarterly Report Q2 FY2003 — Revenue, Net Income, EPS

Summary

Johnson & Johnson reported strong top-line growth for the second quarter and first six months of 2003, with worldwide sales increasing by 13.9% and 13.1% respectively. This growth was driven by robust operational performance across all segments and a favorable currency impact. However, net earnings and earnings per share saw a decline compared to the prior year, primarily due to significant In-Process Research and Development (IPR&D) charges related to strategic acquisitions, notably Scios Inc. and Link Spine Group, Inc. The company continued its aggressive acquisition strategy, with notable additions in the biopharmaceutical and medical device sectors, significantly increasing intangible assets. Despite the impact of acquisition-related charges on profitability, J&J's balance sheet remains strong, with total assets growing and a manageable debt-to-capital ratio. The company also demonstrated its commitment to shareholders by increasing its cash dividend for the 41st consecutive year.

Key Highlights

1Worldwide sales grew by 13.9% in Q2 2003 and 13.1% for the first six months of 2003, driven by strong operational performance and a positive currency impact.
2Net earnings decreased by 26.8% in Q2 and 5.9% for the six months due to significant In-Process Research and Development (IPR&D) charges from acquisitions.
3The company completed several key acquisitions, including Scios Inc. for $2.1 billion and Link Spine Group, Inc. for $325 million (plus contingent payments), significantly increasing intangible assets.
4Pharmaceutical segment operating profit declined by 30.8% in Q2 and 8.9% for the six months, impacted by IPR&D charges and increased spending on sales force expansion.
5Medical Devices & Diagnostics (MD&D) segment showed robust growth, with Q2 operating profit up 19.0% and six-month operating profit up 14.2%, driven by strong sales in key franchises.
6Johnson & Johnson increased its regular cash dividend by 17.1% in the second quarter, marking the 41st consecutive year of dividend increases.
7Total assets grew by 12.6% to $45.7 billion, largely due to acquisitions, while intangible assets increased significantly.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Jun 29, 2003

Summary

Key Highlights

Frequently Asked Questions